ES2394962T3 - Método de diagnóstico de enfermedades inflamatorias usando calgranulina C - Google Patents
Método de diagnóstico de enfermedades inflamatorias usando calgranulina C Download PDFInfo
- Publication number
- ES2394962T3 ES2394962T3 ES03708103T ES03708103T ES2394962T3 ES 2394962 T3 ES2394962 T3 ES 2394962T3 ES 03708103 T ES03708103 T ES 03708103T ES 03708103 T ES03708103 T ES 03708103T ES 2394962 T3 ES2394962 T3 ES 2394962T3
- Authority
- ES
- Spain
- Prior art keywords
- calgranulin
- disease
- patients
- serum
- arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000058242 S100A12 Human genes 0.000 title claims abstract description 256
- 101710110949 Protein S100-A12 Proteins 0.000 title claims abstract description 245
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 41
- 238000002405 diagnostic procedure Methods 0.000 title description 2
- 210000002966 serum Anatomy 0.000 claims abstract description 97
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 76
- 201000010099 disease Diseases 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 46
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 31
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims abstract description 29
- 208000003456 Juvenile Arthritis Diseases 0.000 claims abstract description 26
- 229920001184 polypeptide Polymers 0.000 claims abstract description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 24
- 238000003745 diagnosis Methods 0.000 claims abstract description 23
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims abstract description 23
- 208000019069 chronic childhood arthritis Diseases 0.000 claims abstract description 19
- 239000000523 sample Substances 0.000 claims abstract description 16
- 230000009885 systemic effect Effects 0.000 claims abstract description 14
- 239000013068 control sample Substances 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims description 83
- 206010062164 Seronegative arthritis Diseases 0.000 claims description 16
- 238000002965 ELISA Methods 0.000 claims description 14
- 208000035143 Bacterial infection Diseases 0.000 claims description 13
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 3
- 230000002055 immunohistochemical effect Effects 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 abstract description 28
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 abstract description 2
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 abstract description 2
- 108010005636 polypeptide C Proteins 0.000 abstract 1
- 239000003550 marker Substances 0.000 description 62
- 230000004054 inflammatory process Effects 0.000 description 61
- 206010061218 Inflammation Diseases 0.000 description 59
- 108010074051 C-Reactive Protein Proteins 0.000 description 48
- 102100032752 C-reactive protein Human genes 0.000 description 48
- 230000014509 gene expression Effects 0.000 description 40
- 210000000440 neutrophil Anatomy 0.000 description 38
- 230000009266 disease activity Effects 0.000 description 37
- 208000011231 Crohn disease Diseases 0.000 description 36
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 34
- 229960000485 methotrexate Drugs 0.000 description 34
- 206010009900 Colitis ulcerative Diseases 0.000 description 33
- 201000003883 Cystic fibrosis Diseases 0.000 description 33
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 33
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 33
- 201000006704 Ulcerative Colitis Diseases 0.000 description 33
- 230000009798 acute exacerbation Effects 0.000 description 27
- 238000002560 therapeutic procedure Methods 0.000 description 25
- 229940079593 drug Drugs 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 230000002757 inflammatory effect Effects 0.000 description 22
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 230000001154 acute effect Effects 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 17
- 210000001179 synovial fluid Anatomy 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 14
- 230000003115 biocidal effect Effects 0.000 description 14
- 230000005713 exacerbation Effects 0.000 description 14
- 210000005222 synovial tissue Anatomy 0.000 description 14
- 208000011200 Kawasaki disease Diseases 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000003714 granulocyte Anatomy 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108700016890 S100A12 Proteins 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 208000037976 chronic inflammation Diseases 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 9
- 230000002596 correlated effect Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 210000001503 joint Anatomy 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 102100024484 Codanin-1 Human genes 0.000 description 8
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 206010036790 Productive cough Diseases 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 210000004351 coronary vessel Anatomy 0.000 description 8
- 108010074605 gamma-Globulins Proteins 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 230000000770 proinflammatory effect Effects 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 7
- 241000219061 Rheum Species 0.000 description 7
- 206010047115 Vasculitis Diseases 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000008506 pathogenesis Effects 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 208000024794 sputum Diseases 0.000 description 7
- 210000003802 sputum Anatomy 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 210000001258 synovial membrane Anatomy 0.000 description 7
- 101000653784 Homo sapiens Protein S100-A12 Proteins 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102000054564 human S100A12 Human genes 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 229960000598 infliximab Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000003448 neutrophilic effect Effects 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 5
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 5
- 102000019298 Lipocalin Human genes 0.000 description 5
- 108050006654 Lipocalin Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 230000006020 chronic inflammation Effects 0.000 description 5
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 5
- 238000010820 immunofluorescence microscopy Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 201000004595 synovitis Diseases 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 108010052500 Calgranulin A Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102100032442 Protein S100-A8 Human genes 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 102000013674 S-100 Human genes 0.000 description 4
- 108700021018 S100 Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 206010000269 abscess Diseases 0.000 description 4
- 239000002981 blocking agent Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000008409 synovial inflammation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010052495 Calgranulin B Proteins 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 102100032420 Protein S100-A9 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241000599931 Paris quadrifolia Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 208000006331 coronary aneurysm Diseases 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical group C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- PCDWFBFHIIKIPM-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-2-sulfonic acid Chemical compound C1=CC=C2N(CC)C(S(O)(=O)=O)SC2=C1 PCDWFBFHIIKIPM-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000032492 Bacterial toxic-shock syndrome Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000653791 Bos taurus Protein S100-A12 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010011071 Coronary artery aneurysm Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000144952 Peromyscus californicus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 101150097337 S100A12 gene Proteins 0.000 description 1
- 241000158147 Sator Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043248 Tendon rupture Diseases 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000014387 congenital coronary artery anomaly Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 201000011639 coronary artery anomaly Diseases 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- -1 leukocyte counts Proteins 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 208000012102 polyarticular juvenile rheumatoid arthritis Diseases 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000031339 positive regulation of inflammatory response Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000009498 subcoating Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rehabilitation Therapy (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77600 | 1993-06-15 | ||
| US10/077,600 US20030175713A1 (en) | 2002-02-15 | 2002-02-15 | Method for diagnosis of inflammatory diseases using CALGRANULIN C |
| PCT/EP2003/001575 WO2003069341A2 (en) | 2002-02-15 | 2003-02-17 | Method of diagnosis of inflammatory diseases using calgranulin c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2394962T3 true ES2394962T3 (es) | 2013-02-07 |
Family
ID=27732684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03708103T Expired - Lifetime ES2394962T3 (es) | 2002-02-15 | 2003-02-17 | Método de diagnóstico de enfermedades inflamatorias usando calgranulina C |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20030175713A1 (enExample) |
| EP (1) | EP1474689B1 (enExample) |
| JP (2) | JP5487404B2 (enExample) |
| AU (1) | AU2003212245A1 (enExample) |
| CA (1) | CA2474890A1 (enExample) |
| DK (1) | DK1474689T3 (enExample) |
| ES (1) | ES2394962T3 (enExample) |
| WO (1) | WO2003069341A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030224386A1 (en) * | 2001-12-19 | 2003-12-04 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis |
| US20030175713A1 (en) * | 2002-02-15 | 2003-09-18 | Clemens Sorg | Method for diagnosis of inflammatory diseases using CALGRANULIN C |
| WO2004043238A2 (en) * | 2002-11-14 | 2004-05-27 | Ciphergen Biosystems, Inc. | Biomarkers for intra-amniotic inflammation |
| ATE458201T1 (de) | 2003-12-23 | 2010-03-15 | Hoffmann La Roche | Methode zur beurteilung von rheumatoider arthritis durch bestimmung von anti-ccp und interleukin 6 |
| JP4868378B2 (ja) * | 2004-11-19 | 2012-02-01 | 株式会社明治 | 炎症性腸疾患治療薬 |
| KR101147586B1 (ko) * | 2006-05-19 | 2012-08-23 | 에프. 호프만-라 로슈 아게 | 결장직장암에 대한 마커로서 단백질 ｓ100ａ12 의 용도 |
| DE102007036678B4 (de) * | 2007-08-03 | 2015-05-21 | Sirs-Lab Gmbh | Verwendung von Polynukleotiden zur Erfassung von Genaktivitäten für die Unterscheidung zwischen lokaler und systemischer Infektion |
| WO2009049257A2 (en) * | 2007-10-11 | 2009-04-16 | Cardio Dx, Inc. | Predictive models and methods for diagnosing and assessing coronary artery disease |
| CA2702533A1 (en) * | 2007-10-19 | 2009-04-23 | Erac As | Edta resistant s100a12 complexes (erac) |
| GB0922006D0 (en) * | 2009-12-17 | 2010-02-03 | Genome Res Ltd | Diagnostic |
| WO2011146479A1 (en) * | 2010-05-18 | 2011-11-24 | The Texas A&M University System | Method and composition for the diagnosis and monitoring of inflammatory diseases |
| WO2015067913A1 (en) | 2013-11-07 | 2015-05-14 | Diagnodus Limited | Biomarkers |
| US9678084B2 (en) * | 2011-06-04 | 2017-06-13 | Rochester General Hospital Research Institute | Compositions and methods related to S100A12 |
| WO2013167727A2 (en) | 2012-05-11 | 2013-11-14 | Westfaelische Wilhelms-Universitaet Muenster | Method for determining arthritis relapse risk |
| EP3487874A1 (en) | 2016-07-20 | 2019-05-29 | Westfälische Wilhelms-Universität Münster | Complex-specific standardization of immunological methods for the quantification of s100a12 |
| US11287396B2 (en) | 2020-06-05 | 2022-03-29 | Princeton Biochemicals, Inc. | Method and system for simultaneous determination of multiple measurable biomarkers during the development of a communicable disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455160A (en) * | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| JPH08238091A (ja) * | 1995-03-06 | 1996-09-17 | Jiro Hitomi | 新規カルシウム結合タンパク |
| JPH08238090A (ja) * | 1995-03-06 | 1996-09-17 | Jiro Hitomi | 新規カルシウム結合タンパク |
| EP0731166A3 (en) * | 1995-03-06 | 1997-12-29 | Tonen Corporation | Novel calcium-binding proteins |
| US5976832A (en) * | 1995-03-06 | 1999-11-02 | Tonen Corporation | DNA encoding novel calcium-binding proteins |
| WO2000020621A1 (en) * | 1998-10-06 | 2000-04-13 | The Trustees Of Columbia University In The City Of New York | Extracellular novel rage binding protein (en-rage) and uses thereof |
| US7081241B1 (en) * | 1998-10-06 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Extracellular rage binding protein (EN-RAGE) and uses thereof |
| US6028060A (en) * | 1997-01-29 | 2000-02-22 | Vanderbilt University | Treatment of chronic inflammatory diseases with CM101/GBS toxin |
| US6020135A (en) * | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US7011952B2 (en) * | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| WO2001086002A2 (en) * | 2000-05-09 | 2001-11-15 | Genetics Institute, Llc | Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis |
| AU2001292846A1 (en) * | 2000-09-20 | 2002-04-29 | Surromed, Inc. | Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders |
| WO2002048310A2 (en) * | 2000-12-15 | 2002-06-20 | Genetics Institute, Llc | Methods and compositions for diagnosing and treating rheumatoid arthritis |
| US20030224386A1 (en) * | 2001-12-19 | 2003-12-04 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis |
| US20030175713A1 (en) * | 2002-02-15 | 2003-09-18 | Clemens Sorg | Method for diagnosis of inflammatory diseases using CALGRANULIN C |
-
2002
- 2002-02-15 US US10/077,600 patent/US20030175713A1/en not_active Abandoned
-
2003
- 2003-02-17 ES ES03708103T patent/ES2394962T3/es not_active Expired - Lifetime
- 2003-02-17 WO PCT/EP2003/001575 patent/WO2003069341A2/en not_active Ceased
- 2003-02-17 CA CA002474890A patent/CA2474890A1/en not_active Abandoned
- 2003-02-17 JP JP2003568411A patent/JP5487404B2/ja not_active Expired - Fee Related
- 2003-02-17 US US10/504,299 patent/US20050147972A1/en not_active Abandoned
- 2003-02-17 AU AU2003212245A patent/AU2003212245A1/en not_active Abandoned
- 2003-02-17 DK DK03708103.1T patent/DK1474689T3/da active
- 2003-02-17 EP EP03708103A patent/EP1474689B1/en not_active Expired - Lifetime
-
2009
- 2009-04-13 US US12/422,632 patent/US20170138931A9/en not_active Abandoned
-
2010
- 2010-10-29 JP JP2010244271A patent/JP5650985B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK1474689T3 (da) | 2012-12-03 |
| JP2005517414A (ja) | 2005-06-16 |
| EP1474689A2 (en) | 2004-11-10 |
| WO2003069341A2 (en) | 2003-08-21 |
| JP5650985B2 (ja) | 2015-01-07 |
| AU2003212245A1 (en) | 2003-09-04 |
| US20100311758A1 (en) | 2010-12-09 |
| JP5487404B2 (ja) | 2014-05-07 |
| EP1474689B1 (en) | 2012-09-12 |
| US20050147972A1 (en) | 2005-07-07 |
| US20170138931A9 (en) | 2017-05-18 |
| CA2474890A1 (en) | 2003-08-21 |
| AU2003212245A8 (en) | 2003-09-04 |
| JP2011053222A (ja) | 2011-03-17 |
| WO2003069341A3 (en) | 2004-02-05 |
| US20030175713A1 (en) | 2003-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5650985B2 (ja) | カルグラヌリンｃを用いた炎症性疾患の診断方法 | |
| Kane et al. | Increased perivascular synovial membrane expression of myeloid‐related proteins in psoriatic arthritis | |
| ES2386966T3 (es) | Método para diagnosticar enfermedades infecciosas midiendo el nivel de TREM-1 soluble en una muestra | |
| US11041864B2 (en) | Method for prediction of prognosis of sepsis | |
| US9541560B2 (en) | Serological markers of inflammatory bowel disease phenotype and disease progression | |
| Woei-A-Jin et al. | Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections | |
| ES2369798T3 (es) | Procedimiento de diagnóstico de una enfermedad que implica un anticuerpo antireceptor at1. | |
| de la Fuente et al. | Fibrinolytic activity in cerebrospinal fluid of dogs with different neurological disorders | |
| ES2388082T3 (es) | Procedimiento para el diagnóstico de una enfermedad que implica un anticuerpo antirreceptor de la endotelina | |
| US20140120174A1 (en) | Methods of prognosis and diagnosis of sepsis | |
| Jójárt et al. | Plasminogen activator inhibitor 1 is a novel faecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases | |
| WO2003069349A2 (en) | Method for diagnosis of inflammatory diseases using mrp8/mrp14 | |
| CN110678757B (zh) | 诊断或监测肾功能或诊断肾功能障碍的方法 | |
| US9506923B2 (en) | Method of diagnosing surgical site infections | |
| JP6158825B2 (ja) | テネイシンｃおよび関節リウマチにおけるその使用 | |
| Bañuelos-Andrío et al. | Usefulness of analytical parameters in the management of pediatric patients with suspicion of acute pyelonephritis. Is procalcitonin reliable? | |
| KR102705469B1 (ko) | 불응성 가와사키병의 감별 진단을 위한 정보 제공 방법 | |
| CN117642630A (zh) | 用于非酒精性脂肪肝病的纤维化生物标志物 | |
| KR102494928B1 (ko) | Mrgprx2를 이용한 즉시형 과민 반응 환자를 판별하는 방법 | |
| Sweilam et al. | Study the role of serum cartilage oligomericmatrix protein (COMP) in the diagnosis of rheumatoid arthritis patients | |
| Tuzer et al. | Extended Parasitic Screening in 1154 Adults with Chronic Spontaneous Urticaria: Diagnostic and Therapeutic Insights | |
| JP5010220B2 (ja) | 造血幹細胞移植療法の施行患者の病態把握方法 | |
| JP3220129B2 (ja) | 流早産の可能性の判定方法及びそのための試薬 | |
| Flora Alex et al. | Scholars Journal of Applied Medical Sciences | |
| Siahanidou et al. | Research Article Clinical Value of Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Levels in Term Neonates with Infection or Sepsis: A Prospective Study |